Payment overview · 2025
General Payments
$463.66
25 reported records · 13 companies
Healthcare provider profile · identity verified
Hannah Born, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAMAR, MO · NPI 1134627946
Verified facts
What the public records show
CMS Open Payments records show Hannah Born, NP received $463.66 in general payments during 2025 across 25 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $116.03 | 25.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.41 | 10.0% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $44.89 | 9.7% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $40.98 | 8.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.98 | 8.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.22 | 7.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.02 | 7.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.72 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.13 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.91 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.67 | 3.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.85 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $463.66 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $116.03 | 6 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 52 |
| Lisinopril | Lisinopril | 183 | 56 |
| Meloxicam | Meloxicam | 143 | 46 |
| Omeprazole | Omeprazole | 137 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 40 |
| Gabapentin | Gabapentin | 129 | 47 |
| Furosemide | Furosemide | 128 | 40 |
| Sertraline Hcl | Sertraline Hcl | 116 | 31 |
| Potassium Chloride | Potassium Chloride | 115 | 32 |
| Losartan Potassium | Losartan Potassium | 108 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 24 |
| Methylprednisolone | Methylprednisolone | 86 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 24 |
| Tramadol Hcl | Tramadol Hcl | 80 | 20 |
| Simvastatin | Simvastatin | 79 | 20 |
| Metformin Hcl | Metformin Hcl | 71 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 17 |
| Carvedilol | Carvedilol | 67 | 18 |
| Metformin Hcl Er | Metformin Hcl | 66 | 16 |
| Eliquis | Apixaban | 64 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Allopurinol | Allopurinol | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 24 |
| Trazodone Hcl | Trazodone Hcl | 47 | 18 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Cephalexin | Cephalexin | 43 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Azithromycin | Azithromycin | 39 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 30 |
| Atenolol | Atenolol | 32 | suppressed |
| Prednisone | Prednisone | 30 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Finasteride | Finasteride | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Nystatin | Nystatin | 20 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $463.66 · 25 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, CAPLYTA, EPIDIOLEX, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VUMERITY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error